<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="nihpa"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC5581215/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Genome-wide association study of cardiotoxicity in NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581215/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Pharmacogenetics and genomics"><meta name="citation_title" content="Genome-wide association study of cardiotoxicity in NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial"><meta name="citation_authors" content="DJ Serie, JE Crook, BM Necela, TJ Dockter, X Wang, YW Asmann, D Fairweather, KA Bruno, G Colon-Otero, EA Perez, EA Thompson, N Norton"><meta name="citation_date" content="October 2017"><meta name="citation_issue" content="10"><meta name="citation_volume" content="27"><meta name="citation_firstpage" content="378"><meta name="citation_doi" content="10.1097/FPC.0000000000000302"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC5581215/?report=abstract"><meta name="citation_pmid" content="28763429"><meta name="DC.Title" content="Genome-wide association study of cardiotoxicity in NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="NIH Public Access"><meta name="DC.Contributor" content="DJ Serie"><meta name="DC.Contributor" content="JE Crook"><meta name="DC.Contributor" content="BM Necela"><meta name="DC.Contributor" content="TJ Dockter"><meta name="DC.Contributor" content="X Wang"><meta name="DC.Contributor" content="YW Asmann"><meta name="DC.Contributor" content="D Fairweather"><meta name="DC.Contributor" content="KA Bruno"><meta name="DC.Contributor" content="G Colon-Otero"><meta name="DC.Contributor" content="EA Perez"><meta name="DC.Contributor" content="EA Thompson"><meta name="DC.Contributor" content="N Norton"><meta name="DC.Date" content="2017 Oct"><meta name="DC.Identifier" content="10.1097/FPC.0000000000000302"><meta name="DC.Language" content="en"><meta property="og:title" content="Genome-wide association study of cardiotoxicity in NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial"><meta property="og:type" content="article"><meta property="og:description" content="The major clinical side-effect of the ERBB2 targeted breast cancer therapy, trastuzumab, is a decline in left ventricular ejection fraction (LVEF). Improved markers are needed to better identify patients susceptible to cardiotoxicity.The NCCTG N9831 trial ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581215/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><meta name="ncbi_feature" content="associated_data"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript" src="/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC5581215/epub/"><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC5581215/pdf/nihms892344.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="CE8C098BDD5A65C10000000005E90382.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1px; bottom: 2px; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/jax/output/HTML-CSS/config.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/jax/input/MathML/config.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/jax/output/NativeMML/config.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/mml2jax.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/MathEvents.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/MathZoom.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/MathMenu.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/toMathML.js?rev=2.6.1"></script></head>
    <body class="article" id="ui-ncbiexternallink-4"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5581215%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox" type="text"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a></li><li class="accid">PMC5581215</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-hhspa.png" alt="Logo of nihpa" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,57,255,75" alt="About Author manuscripts" title="About Author manuscripts" href="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" ref="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html"><area shape="rect" coords="256,57,500,75" alt="Submit a manuscript" title="Submit a manuscript" href="https://www.nihms.nih.gov/" ref="reftype=publisher&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="0,0,499,74" alt="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" title="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" href="https://www.ncbi.nlm.nih.gov/pmc/about/public-access/" ref="reftype=publisher&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">Pharmacogenet Genomics</a></span>. Author manuscript; available in PMC 2018 Oct 1.</div><div></div><div>Published in final edited form as:</div><div style="margin-left:1em"><div class="fm-vol-iss-date"><a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=28763429" target="pmc_ext" ref="reftype=publisher&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access"><span class="cit">Pharmacogenet Genomics. 2017 Oct; 27(10): 378–385. </span></a></div> <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1097%2FFPC.0000000000000302" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1097/FPC.0000000000000302</a></span></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC5581215</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS892344</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/28763429">28763429</a></div></div></div></div><h1 class="content-title">Genome-wide association study of cardiotoxicity in NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Serie%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429" class="affpopup" co-rid="_co_idm140277539242976" co-class="co-affbox">DJ Serie</a>,<sup>1</sup> <a href="/pubmed/?term=Crook%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429" class="affpopup" co-rid="_co_idm140277503269984" co-class="co-affbox">JE Crook</a>,<sup>1</sup> <a href="/pubmed/?term=Necela%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429" class="affpopup" co-rid="_co_idm140277498439792" co-class="co-affbox">BM Necela</a>,<sup>2</sup> <a href="/pubmed/?term=Dockter%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429" class="affpopup" co-rid="_co_idm140277503489328" co-class="co-affbox">TJ Dockter</a>,<sup>3</sup> <a href="/pubmed/?term=Wang%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429" class="affpopup" co-rid="_co_idm140277503487792" co-class="co-affbox">X Wang</a>,<sup>1</sup> <a href="/pubmed/?term=Asmann%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429" class="affpopup" co-rid="_co_idm140277503735296" co-class="co-affbox">YW Asmann</a>,<sup>1</sup> <a href="/pubmed/?term=Fairweather%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429" class="affpopup" co-rid="_co_idm140277509328480" co-class="co-affbox">D Fairweather</a>,<sup>4</sup> <a href="/pubmed/?term=Bruno%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429" class="affpopup" co-rid="_co_idm140277500930272" co-class="co-affbox">KA Bruno</a>,<sup>4</sup> <a href="/pubmed/?term=Colon-Otero%20G%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429" class="affpopup" co-rid="_co_idm140277500928288" co-class="co-affbox">G Colon-Otero</a>,<sup>5</sup> <a href="/pubmed/?term=Perez%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429" class="affpopup" co-rid="_co_idm140277510706416" co-class="co-affbox">EA Perez</a>,<sup>5</sup> <a href="/pubmed/?term=Thompson%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429" class="affpopup" co-rid="_co_idm140277508873808" co-class="co-affbox">EA Thompson</a>,<sup>2</sup> and  <a href="/pubmed/?term=Norton%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429" class="affpopup" co-rid="_co_idm140277505783152" co-class="co-affbox">N Norton</a><sup>2,</sup><sup>*</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140277539242976"><h3 class="no_margin">DJ Serie</h3><p>  <sup>1</sup>Health Sciences Research, Mayo Clinic, Jacksonville, FL</p><div>Find articles by <a href="/pubmed/?term=Serie%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429">DJ Serie</a></div></div><div id="_co_idm140277503269984"><h3 class="no_margin">JE Crook</h3><p>  <sup>1</sup>Health Sciences Research, Mayo Clinic, Jacksonville, FL</p><div>Find articles by <a href="/pubmed/?term=Crook%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429">JE Crook</a></div></div><div id="_co_idm140277498439792"><h3 class="no_margin">BM Necela</h3><p>  <sup>2</sup>Department of Cancer Biology, Mayo Clinic, Jacksonville, FL</p><div>Find articles by <a href="/pubmed/?term=Necela%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429">BM Necela</a></div></div><div id="_co_idm140277503489328"><h3 class="no_margin">TJ Dockter</h3><p>  <sup>3</sup>Health Sciences Research, Mayo Clinic, Rochester, MN</p><div>Find articles by <a href="/pubmed/?term=Dockter%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429">TJ Dockter</a></div></div><div id="_co_idm140277503487792"><h3 class="no_margin">X Wang</h3><p>  <sup>1</sup>Health Sciences Research, Mayo Clinic, Jacksonville, FL</p><div>Find articles by <a href="/pubmed/?term=Wang%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429">X Wang</a></div></div><div id="_co_idm140277503735296"><h3 class="no_margin">YW Asmann</h3><p>  <sup>1</sup>Health Sciences Research, Mayo Clinic, Jacksonville, FL</p><div>Find articles by <a href="/pubmed/?term=Asmann%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429">YW Asmann</a></div></div><div id="_co_idm140277509328480"><h3 class="no_margin">D Fairweather</h3><p>  <sup>4</sup>Department of Cardiovascular Diseases, Mayo Clinic, Jacksonville, FL</p><div>Find articles by <a href="/pubmed/?term=Fairweather%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429">D Fairweather</a></div></div><div id="_co_idm140277500930272"><h3 class="no_margin">KA Bruno</h3><p>  <sup>4</sup>Department of Cardiovascular Diseases, Mayo Clinic, Jacksonville, FL</p><div>Find articles by <a href="/pubmed/?term=Bruno%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429">KA Bruno</a></div></div><div id="_co_idm140277500928288"><h3 class="no_margin">G Colon-Otero</h3><p>  <sup>5</sup>Hematology/Oncology, Mayo Clinic, Jacksonville, FL</p><div>Find articles by <a href="/pubmed/?term=Colon-Otero%20G%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429">G Colon-Otero</a></div></div><div id="_co_idm140277510706416"><h3 class="no_margin">EA Perez</h3><p>  <sup>5</sup>Hematology/Oncology, Mayo Clinic, Jacksonville, FL</p><div>Find articles by <a href="/pubmed/?term=Perez%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429">EA Perez</a></div></div><div id="_co_idm140277508873808"><h3 class="no_margin">EA Thompson</h3><p>  <sup>2</sup>Department of Cancer Biology, Mayo Clinic, Jacksonville, FL</p><div>Find articles by <a href="/pubmed/?term=Thompson%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429">EA Thompson</a></div></div><div id="_co_idm140277505783152"><h3 class="no_margin">N Norton</h3><p>  <sup>2</sup>Department of Cancer Biology, Mayo Clinic, Jacksonville, FL</p><div>Find articles by <a href="/pubmed/?term=Norton%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28763429">N Norton</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140277502283760_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140277502283760_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140277502283760_ai" style="display:none"><div class="fm-affl" id="A1" lang="en">  <sup>1</sup>Health Sciences Research, Mayo Clinic, Jacksonville, FL</div><div class="fm-affl" id="A2" lang="en">  <sup>2</sup>Department of Cancer Biology, Mayo Clinic, Jacksonville, FL</div><div class="fm-affl" id="A3" lang="en">  <sup>3</sup>Health Sciences Research, Mayo Clinic, Rochester, MN</div><div class="fm-affl" id="A4" lang="en">  <sup>4</sup>Department of Cardiovascular Diseases, Mayo Clinic, Jacksonville, FL</div><div class="fm-affl" id="A5" lang="en">  <sup>5</sup>Hematology/Oncology, Mayo Clinic, Jacksonville, FL</div><div id="FN1"><sup>*</sup><strong>Corresponding Author:</strong> Nadine Norton, PhD, Department of Cancer Biology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, Florida 32224, Tel: 904-953-6352, Fax: 904-953-6233, <a href="mailto:dev@null" data-email="ude.oyam@enidaN.notroN" class="oemail">ude.oyam@enidaN.notroN</a></div></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="permissions fm-panel half_rhythm hide" id="idm140277502283760_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>The publisher's final edited version of this article is available  at <a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=28763429" target="pmc_ext" ref="reftype=publisher&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">Pharmacogenet Genomics</a></div><div>See other articles in PMC that <a href="/pmc/articles/PMC5581215/citedby/">cite</a> the published article.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="ui-helper-clearfix" id="ui-ncbiinpagenav-heading-3">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supplemental Digital Content_clean.</strong></div><div><a href="/pmc/articles/PMC5581215/bin/NIHMS892344-supplement-Supplemental_Digital_Content_clean.docx" data-ga-action="click_feat_suppl">NIHMS892344-supplement-Supplemental_Digital_Content_clean.docx</a><span style="color:gray"> (1.7M)</span></div><div class="small guid">GUID:&nbsp;4840C711-32AE-4EBC-917E-2EBCBF7BB816</div></div></dd></dl></div><div id="idm140277541413312" class="tsec sec" lang="en"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140277541413312title">Abstract</h2><!--article-meta--><div><div id="S1" class="sec sec-first"><h3 id="S1title">Objectives</h3><p id="P1" class="p p-first-last">The major clinical side-effect of the <em>ERBB2</em> targeted breast cancer therapy, trastuzumab, is a decline in left ventricular ejection fraction (LVEF). Improved markers are needed to better identify patients susceptible to cardiotoxicity.</p></div><div id="S2" class="sec"><h3 id="S2title">Methods</h3><p id="P2" class="p p-first-last">The NCCTG N9831 trial compared adjuvant doxorubicin and cyclophosphamide followed by either weekly paclitaxel (Arm A); paclitaxel then trastuzumab (Arm B); or concurrent paclitaxel and trastuzumab (Arm C) in patients with HER2-positive breast cancer. A GWAS was performed on all patients with available DNA (N=1,446). We used linear regression to identify SNPs associated with decline in LVEF, adjusting for age, baseline LVEF, anti-hypertensive medications and the first two principle components.</p></div><div id="S3" class="sec"><h3 id="S3title">Results</h3><p id="P3" class="p p-first-last">618,863 SNPs passed quality control (QC) and DNA from 1,191 patients passed genotyping QC and were identified as whites of non-Hispanic origin. SNPs at six loci were associated with a decline in LVEF (p=7.73×10<sup>−6</sup> to 8.93×10<sup>−8</sup>), <em>LDB2</em>, <em>BRINP1</em>, chr6 intergenic, <em>RAB22A</em>, <em>TRPC6</em> and <em>LINC01060</em>, in patients who received chemotherapy plus trastuzumab (Arms BC, N=800). None of these loci were significant in patients who received chemotherapy only (Arm A, N=391) and did not increase in significance in analysis of all patients combined. We did not observe association, p&lt;0.05 with SNPs previously associated with trastuzumab induced cardiotoxicity at <em>ERBB2</em>, I655V and P1170A. We replicated association, p&lt;0.05, with SNPs previously associated with anthracycline cardiotoxicity at <em>CBR3</em> and <em>ABCB1</em>.</p></div><div id="S4" class="sec sec-last"><h3 id="S4title">Conclusions</h3><p id="P4" class="p p-first-last">Our study identified six putative novel cardiotoxicity loci in patients treated with combination chemotherapy and trastuzumab that require further investigation and confirmed known associations of anthracycline-induced cardiotoxicity.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">trastuzumab, doxorubicin, breast cancer, GWAS, cardiotoxicity, cardio-oncology, ERBB2, CBR3, ABCB1</span></div></div><div id="S5" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S5title">Introduction</h2><p id="P5" class="p p-first">The targeted ERBB2 therapy, trastuzumab, has had a tremendous impact on the management of patients with HER2+ advanced and early breast cancer. The major adverse event for this drug is cardiotoxicity, but symptoms are not uniform across patients and differ from the well-known dose-dependent effect of anthracyclines<sup><a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338411">1</a></sup>.</p><p id="P6">There are no clinically proven markers to predict which patients will experience cardiotoxicity following trastuzumab treatment. Left ventricular ejection fraction (LVEF) &lt;55%, age &gt;60 years, and antihypertensive medication prior to treatment are known risk factors<sup><a href="#R2" rid="R2" class=" bibr popnode">2</a></sup>. The observed variability of cardiac symptoms in humans and animal models suggest a genetic influence. ErbB2-deficient conditional mutant adult mice develop a phenotype consistent with dilated cardiomyopathy (DCM)<sup><a href="#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338407">3</a>,<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338377">4</a></sup>. Some forms of heart disease presenting with decreased LVEF in humans, such as familial dilated and hypertrophic cardiomyopathy, are known to have a strong heterogeneous genetic basis<sup><a href="#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338391">5</a></sup>. 197 published rare variants in more than 30 causative genes have been reported in the literature<sup><a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338413">6</a></sup>. Common variants in these genes are over-represented in sporadic cases<sup><a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338414">7</a>–<a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338420">9</a></sup> suggesting the existence of modifying or risk variants that could be exacerbated by environmental stress factors such as trastuzumab and/or chemotherapy. To date, two common genetic polymorphisms within <em>ERBB2</em>, Ile655Val and Pro1170Ala, have been associated with an increased risk of trastuzumab-related cardiotoxicity, but sample sizes were small (N ranging 61–140 patients)<sup><a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338415">10</a>–<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338390">14</a></sup>. Polymorphisms in several genes including <em>ABCB1</em>, <em>CBR3</em><sup><a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338399">15</a>,<a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338401">16</a></sup>, <em>RAC2</em>, <em>NCF4</em><sup><a href="#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338408">17</a>,<a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338424">18</a></sup> and <em>SLC28A3</em><sup><a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338378">19</a>,<a href="#R20" rid="R20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338400">20</a></sup> have been associated with anthracycline-related cardiotoxicity.</p><p id="P7">Trastuzumab-related cardiotoxicity commonly manifests as an asymptomatic decline in LVEF that is mostly reversible when treatment is stopped. However, it remains unclear whether trastuzumab therapy could have long-lasting effects on cardiac function such as progressive cardiac remodeling and DCM. This adverse effect of trastuzumab has resulted in strict eligibility criteria in clinical trials and/or discontinuation prior to completion of treatment; 5% of almost 3,500 eligible patients in the NSABP-B31 and N9831 trials were not allowed to initiate trastuzumab therapy and a further 5% of initially eligible women discontinued treatment due to cardiac side effects<sup><a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338412">21</a>,<a href="#R22" rid="R22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338389">22</a></sup>. Data from multiple randomized adjuvant trials and observational studies suggest that the rate of discontinuation of trastuzumab treatment ranges between 6–31%, mainly due to cardiotoxicity. In patients aged ≥65 years old, this figure increases to a notable and clinically relevant rate of 41%<sup><a href="#R23" rid="R23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_636172236">23</a></sup>. Identification of genetic variants that predict which patients are predisposed to cardiotoxicity could improve patient treatment and management.</p><p id="P8" class="p p-last">Observations of trastuzumab related cardiotoxicity are further complicated by the use of anthracyclines prior to trastuzumab treatment, particularly as anthracyclines can result in late-onset cardiac dysfunction<sup><a href="#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338432">24</a></sup>. All patients in the N9831 study received anthracyclines and paclitaxel prior to trastuzumab. The patients who had LVEF dysfunction at 6 years follow-up were the same patients who had LVEF dysfunction during trastuzumab-paclitaxel therapy<sup><a href="#R25" rid="R25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338376">25</a></sup>. In addition, LVEF dysfunction at 6 years was not statistically different among the chemotherapy only and chemotherapy plus trastuzumab treatment arms, so long-term LVEF dysfunction may not be related to trastuzumab but, possibly, to exposure to anthracyclines and/or increasing age. This is an important point because identification of genetic variants that predict which patients are predisposed to anthracycline cardiotoxicity could allow these patients to use a different chemotherapy regimen, allowing them to be eligible for and to complete trastuzumab therapy. The large size, design and detailed cardiac data collected in N9831 allowed us to examine the genetic influence of trastuzumab on cardiotoxicity in the context of both anthracycline chemotherapy and combination chemotherapy and trastuzumab.</p></div><div id="S6" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S6title">Methods</h2><p id="P9" class="p p-first">Detailed information about the methods and study population are available in <a href="#SD1" rid="SD1" class=" supplementary-material">supplemental material</a>. Briefly, genome-wide genotyping was performed by Affymetrix Axiom array from which 618,793 SNPs passed genotyping quality control. Primary analysis consisted of patients from N9831, Arms BC (N=800 individuals) who received doxorubicin, paclitaxel and trastuzumab (<a href="/pmc/articles/PMC5581215/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>). We performed statistical analyses using R version 3.1.1, PLINK version 1.07 and Locus Zoom<sup><a href="#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338422">26</a></sup>. Linear regression was used for change in LVEF (lowest recorded LVEF - baseline LVEF), adjusting for age, baseline LVEF, anti-hypertensive medications and the first two principle components in the 800 patients in Arms BC who received combination chemotherapy and trastuzumab.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC5581215/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140277500023584" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.
Object name is nihms892344f1.jpg" title="An external file that holds a picture, illustration, etc.
Object name is nihms892344f1.jpg" src="/pmc/articles/PMC5581215/bin/nihms892344f1.jpg"></div></a><div id="largeobj_idm140277500023584" class="largeobj-link align_right" style="display: none"><a href="/pmc/articles/PMC5581215/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"></a><a target="object" href="/pmc/articles/PMC5581215/figure/F1/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC5581215/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Treatment Arms and cardiac monitoring of N9831</strong><p id="__p3">A, Doxorubicin 60 mg/m<sup>2</sup>; C, Cyclophosphamide 600mg/m<sup>2</sup>; paclitaxel 80 mg/m<sup>2</sup>; trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly (qw); LVEF, left ventricular ejection fraction.</p></div></div></div><p id="P10" class="p p-last">We report novel associations at p&lt;1×10<sup>−5</sup> in these patients. We also report on published associations of trastuzumab-related cardiotoxicity of the variants <em>ERBB2</em> Ile655Val and Pro1170Ala<sup><a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338398">10</a>,<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338385">12</a>–<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338416">14</a></sup> from patients in Arms BC and on published associations of anthracycline-related cardiotoxicity at the <em>ABCB1</em>, <em>CBR3</em>, <em>RAC2</em>, <em>NCF4</em>, <em>SLC28A3</em>, <em>RARG</em> and <em>UGT1A6</em> loci<sup><a href="#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338419">27</a></sup> in patients from Arms A, B and C combined, who all received doxorubicin and paclitaxel.</p></div><div id="S7" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S7title">Results</h2><div id="S8" class="sec sec-first"><h3 id="S8title">Suggestive loci associated with combination chemotherapy and trastuzumab induced decline in LVEF</h3><p id="P11" class="p p-first">Seeking modifying/susceptibility genes for cardiotoxicity in patients undergoing treatment for HER2-positive breast cancer, we used a genome-wide association approach. Our primary analysis consisted of DNA samples from 800 patients (Arms BC) who received doxorubicin, paclitaxel and trastuzumab and were determined to be of White/non-Hispanic origin with complete LVEF data from baseline (prior to doxorubicin) and up to two years post treatment.</p><p id="P12">This analysis yielded six regions at p&lt;1×10<sup>−5</sup>, with associated variants within or close to <em>LDB2</em>, <em>BRINP1</em>, an intergenic region on chromosome 6, <em>RAB22A</em>, <em>TRPC6</em> and <em>LINC01060</em> (<a href="/pmc/articles/PMC5581215/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>), (QQ and Manhattan plots, <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure 2</a>). Locus zoom plots of each region are shown in <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure 3</a>. The most significant variant, rs55756123, p=8.93×10<sup>−8</sup> mapped within 500bp of the 3′UTR of <em>LDB2</em>. Imputation did not identify any additional variants at this level of significance or any additional coding variants at p&lt;0.05. In the subset of patients with congestive heart failure (CHF) (N=10) versus those without (N=789), a Fisher’s exact test of rs55756123 genotype counts was significant, p=0.007, suggesting enrichment of the associated allele in individuals with the worst cardiac outcome.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Linear regression analysis of maximum decline in LVEF</strong><p id="__p4">SNP ID, Chr, chromosome and Hg19 position. MAF, minor allele frequency, L95, lower and U95 upper 95% confidence intervals and P, p-value, is shown for Arms BC and Arm A additive linear regression analysis. Genotype count for each SNP is shown in the subset of patients with CHF, congestive heart failure, separated for Arms BC and Arm A, with genotype counts of allele 1 homozygote/heterozygote/allele 2 homozygote and minor allele frequency in parentheses.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140277506645440" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="2" colspan="1" valign="bottom" align="left">ID</th><th rowspan="2" colspan="1" valign="bottom" align="right">Chr</th><th rowspan="2" colspan="1" valign="bottom" align="left">Position Hg19</th><th rowspan="2" colspan="1" valign="bottom" align="left">Locus</th><th colspan="3" rowspan="1" valign="bottom" align="left">Arms BC- Max Drop in LVEF (N=800)</th><th colspan="3" rowspan="1" valign="bottom" align="left">Arm A- Max Drop in LVEF (N=391)</th><th colspan="2" rowspan="1" valign="bottom" align="left">CHF (n=17) genotype count and (MAF)</th></tr><tr><th rowspan="1" colspan="1" valign="bottom" align="left">MAF</th><th rowspan="1" colspan="1" valign="bottom" align="left">Beta (L95−U95)</th><th rowspan="1" colspan="1" valign="bottom" align="left">P (2−tail)</th><th rowspan="1" colspan="1" valign="bottom" align="left">MAF</th><th rowspan="1" colspan="1" valign="bottom" align="left">Beta (L95−U95)</th><th rowspan="1" colspan="1" valign="bottom" align="left">P (2−tail)</th><th rowspan="1" colspan="1" valign="bottom" align="left">Arms BC</th><th rowspan="1" colspan="1" valign="bottom" align="left">Arm A</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">rs55756123</td><td rowspan="1" colspan="1" valign="top" align="right">4</td><td rowspan="1" colspan="1" valign="top" align="left">16,502,767</td><td rowspan="1" colspan="1" valign="top" align="left">LDB2</td><td rowspan="1" colspan="1" valign="top" align="left">0.02</td><td rowspan="1" colspan="1" valign="top" align="left">−6.11 (−8.32 to −3.89)</td><td rowspan="1" colspan="1" valign="top" align="left">8.93E-08</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">1.61 (−3.82 to 7.04)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/3/7 (0.15)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs10117876</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,859,107</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.79 (−10.82 to −4.76)</td><td rowspan="1" colspan="1" valign="top" align="left">5.86E-07</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">2.12 (−3.35 to 7.59)</td><td rowspan="1" colspan="1" valign="top" align="left">0.44</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs7038023</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,859,198</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.79 (−10.82 to −4.76)</td><td rowspan="1" colspan="1" valign="top" align="left">5.86E-07</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">1.83 (−3.26 to 6.92)</td><td rowspan="1" colspan="1" valign="top" align="left">0.48</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs7041012</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,859,463</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.18 (−10.06 to −4.29)</td><td rowspan="1" colspan="1" valign="top" align="left">1.34E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">1.16 (−3.92 to 6.24)</td><td rowspan="1" colspan="1" valign="top" align="left">0.66</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs1160584</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,861,009</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.91 (−11.12 to −4.70)</td><td rowspan="1" colspan="1" valign="top" align="left">1.62E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">2.85 (−3.64 to 9.35)</td><td rowspan="1" colspan="1" valign="top" align="left">0.38</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs230145</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,879,897</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.91 (−11.12 to −4.70)</td><td rowspan="1" colspan="1" valign="top" align="left">1.62E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.76 (−7.70 to 4.18)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs230144</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,882,710</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.90 (−11.12 to −4.69)</td><td rowspan="1" colspan="1" valign="top" align="left">1.70E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.76 (−7.70 to 4.19)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs230142</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,883,736</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.91 (−11.12 to −4.70)</td><td rowspan="1" colspan="1" valign="top" align="left">1.62E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.76 (−7.70 to 4.18)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs62573809</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,892,448</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−6.88 (−9.84 to −3.93)</td><td rowspan="1" colspan="1" valign="top" align="left">5.70E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−2.25 (−7.69 to 3.20)</td><td rowspan="1" colspan="1" valign="top" align="left">0.42</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs16908078</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,893,380</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.49 (−10.61 to −4.38)</td><td rowspan="1" colspan="1" valign="top" align="left">2.95E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.76 (−7.70 to 4.18)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs7851490</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,894,217</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.48 (−10.60 to −4.36)</td><td rowspan="1" colspan="1" valign="top" align="left">3.12E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.76 (−7.70 to 4.18)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs7854066</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,899,889</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.49 (−10.61 to −4.37)</td><td rowspan="1" colspan="1" valign="top" align="left">3.04E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.76 (−7.70 to 4.18)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs62573837</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,900,834</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.50 (−10.62 to −4.38)</td><td rowspan="1" colspan="1" valign="top" align="left">2.88E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.76 (−7.70 to 4.18)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs76586195</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,902,640</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.73 (−10.95 to −4.52)</td><td rowspan="1" colspan="1" valign="top" align="left">2.90E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.76 (−7.70 to 4.18)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs7027658</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,904,365</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.49 (−10.61 to −4.38)</td><td rowspan="1" colspan="1" valign="top" align="left">2.95E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.76 (−7.70 to 4.18)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs75912020</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,909,304</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.49 (−10.61 to −4.38)</td><td rowspan="1" colspan="1" valign="top" align="left">2.95E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.77 (−7.71 to 4.18)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs76890184</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,910,252</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.49 (−10.61 to −4.38)</td><td rowspan="1" colspan="1" valign="top" align="left">2.95E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.76 (−7.70 to 4.18)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs58944852</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,912,974</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.49 (−10.61 to −4.38)</td><td rowspan="1" colspan="1" valign="top" align="left">2.87E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.76 (−7.70 to 4.18)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs62568637</td><td rowspan="1" colspan="1" valign="top" align="right">9</td><td rowspan="1" colspan="1" valign="top" align="left">121,917,144</td><td rowspan="1" colspan="1" valign="top" align="left">BRINP1</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−8.50 (−11.81 to −5.19)</td><td rowspan="1" colspan="1" valign="top" align="left">6.01E-07</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−1.77 (−7.72 to 4.18)</td><td rowspan="1" colspan="1" valign="top" align="left">0.56</td><td rowspan="1" colspan="1" valign="top" align="left">0/1/9 (0.05)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs4305714</td><td rowspan="1" colspan="1" valign="top" align="right">6</td><td rowspan="1" colspan="1" valign="top" align="left">22,957,737</td><td rowspan="1" colspan="1" valign="top" align="left">intergenic</td><td rowspan="1" colspan="1" valign="top" align="left">0.24</td><td rowspan="1" colspan="1" valign="top" align="left">−1.87 (−2.63 to −1.12)</td><td rowspan="1" colspan="1" valign="top" align="left">1.39E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.24</td><td rowspan="1" colspan="1" valign="top" align="left">−0.51 (−1.64 to 0.63)</td><td rowspan="1" colspan="1" valign="top" align="left">0.38</td><td rowspan="1" colspan="1" valign="top" align="left">0/5/5 (0.25)</td><td rowspan="1" colspan="1" valign="top" align="left">1/5/1 (0.50)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs707557</td><td rowspan="1" colspan="1" valign="top" align="right">20</td><td rowspan="1" colspan="1" valign="top" align="left">56,942,312</td><td rowspan="1" colspan="1" valign="top" align="left">RAB22A</td><td rowspan="1" colspan="1" valign="top" align="left">0.40</td><td rowspan="1" colspan="1" valign="top" align="left">1.46 (0.83 to 2.08)</td><td rowspan="1" colspan="1" valign="top" align="left">5.62E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.38</td><td rowspan="1" colspan="1" valign="top" align="left">−0.31 (−1.33 to 0.71)</td><td rowspan="1" colspan="1" valign="top" align="left">0.55</td><td rowspan="1" colspan="1" valign="top" align="left">1/3/6 (0.25)</td><td rowspan="1" colspan="1" valign="top" align="left">1/6/0 (0.57)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs77679196</td><td rowspan="1" colspan="1" valign="top" align="right">11</td><td rowspan="1" colspan="1" valign="top" align="left">101,453,508</td><td rowspan="1" colspan="1" valign="top" align="left">TRPC6</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−7.00 (−10.05 to −3.96)</td><td rowspan="1" colspan="1" valign="top" align="left">7.72E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.01</td><td rowspan="1" colspan="1" valign="top" align="left">−5.29 (−11.95 to 1.38)</td><td rowspan="1" colspan="1" valign="top" align="left">0.12</td><td rowspan="1" colspan="1" valign="top" align="left">0/2/8 (0.10)</td><td rowspan="1" colspan="1" valign="top" align="left">0/0/7 (0.00)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs7698718</td><td rowspan="1" colspan="1" valign="top" align="right">4</td><td rowspan="1" colspan="1" valign="top" align="left">189,555,947</td><td rowspan="1" colspan="1" valign="top" align="left">LINC01060</td><td rowspan="1" colspan="1" valign="top" align="left">0.22</td><td rowspan="1" colspan="1" valign="top" align="left">1.78 (1.01 to 2.56)</td><td rowspan="1" colspan="1" valign="top" align="left">7.73E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.22</td><td rowspan="1" colspan="1" valign="top" align="left">0.11 (−1.02 to 1.23)</td><td rowspan="1" colspan="1" valign="top" align="left">0.86</td><td rowspan="1" colspan="1" valign="top" align="left">1/2/7 (0.20)</td><td rowspan="1" colspan="1" valign="top" align="left">0/5/2 (0.36)</td></tr></tbody></table></div><div id="largeobj_idm140277506645440" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC5581215/table/T1/?report=objectonly">Open in a separate window</a></div></div><p id="P13">We observed a total of 18 SNPs, p&lt;1×10<sup>−5</sup> at the <em>BRINP1</em> locus; the most significant an intronic variant, rs62568637, p=6.01×10<sup>−7</sup> and variants in the 3′ flanking region, rs10117876 and rs7038023, p=5.86×10<sup>−7</sup> in high LD, r<sup>2</sup>=0.815. Of note, rs62568637 and flanking SNPs on either side showed positive GERP scores (ranging 1.46–4.51) suggestive of sequence conservation (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Table 4</a>). Imputation at this region identified a more significant 3′ flanking variant, rs7037449, p=1.87×10<sup>−7</sup> in high LD with the other 3′ flanking variants.</p><p id="P14">rs4305714, p=1.39×10<sup>−6</sup> maps to an intergenic region on chromosome 6p22.3. Imputation across the region was supportive, yielding an additional 18 variants at p&lt;1×10<sup>−5</sup> and two additional variants in high LD, rs72836853 and rs10485148 at p=9.85×10<sup>−7</sup>.</p><p id="P15">A common variant (MAF=0.40) within the 3′UTR of <em>RAB22A</em>, rs707557, was associated at p=5.62×10<sup>−6</sup>. The positive GERP score for this variant (2.47) may suggest some level of sequence conservation at this locus. Imputation across this region yielded two additional SNPs at the same level of significance in very high LD, rs1045408 and rs6128327, p=3.48 and 3.38×10<sup>−6</sup>, respectively, both of which map to sequences with very high GERP scores (ranging 4.32–5.40).</p><p id="P16">An intronic variant, rs77679196, within <em>TRPC6</em> was associated at p=7.72×10<sup>−6</sup>. Imputation across the region yielded one additional SNP in the 5′ flanking region, with a slightly stronger association, rs75865789, beta= −8.62 (95% CI −12.07 to −5.178), p=1.14×10<sup>−6</sup>. In the subset of patients with CHF (N=10) versus those without (N=789), a Fisher’s exact test of rs77679196 genotype counts was significant (p=0.019) suggesting enrichment of the associated allele in individuals with the worst cardiac outcome.</p><p id="P17">Associated variants in the final significant region were entirely intergenic, the closest gene being <em>LINC01060</em>. Imputation supported the most significant SNP, rs7698718, with an additional variant at p&lt;1×10<sup>−5</sup> all in high LD, but no variants of greater association were identified.</p><p id="P18" class="p p-last">We reasoned that variants associated with cardiotoxicity specifically from doxorubicin would be significant or show a trend in the chemotherapy Arm only and report these data separately in <a href="/pmc/articles/PMC5581215/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>. None of the six regions from our discovery analyses of patients who received chemotherapy in combination with trastuzumab (N=800) were significant at p&lt;0.05 (1 tailed) in the patients who received chemotherapy only (N=391). <em>LDB2</em> and <em>RAB22A</em> showed an effect in the opposite direction in patients who received chemotherapy only, and combined analyses of all patients (N=1,191) became less significant, p=1.81×10<sup>−6</sup> and p=0.0015, respectively. The most significant SNPs at <em>BRINP1</em> and the intergenic region close to <em>LINC01060</em> showed effects in the same direction and became slightly more significant in combined analyses of all patients (N=1,191), <em>BRINP1</em>, rs62568637, p=4.73×10<sup>−6</sup>; LINC01060, p=1.63×10<sup>−6</sup>. The intergenic SNP, rs4305714 became less significant in the combined analysis of all patients, p=1.20×10<sup>−5</sup>. rs7769196 in intron 1 of <em>TRPC6</em> did show a similar effect size in the same direction and a trend for association (p=0.06,1-tailed) in patients who received chemotherapy only, increasing in significance in combined analysis of all patients, p=1.63×10<sup>−6</sup>.</p></div><div id="S9" class="sec"><h3 id="S9title">Replication of variants associated with ERBB2-induced cardiotoxicity</h3><p id="P19" class="p p-first">Our study failed to find association of decline in LVEF with either of the published associated <em>ERBB2</em> variants, rs1136201 (I655V) and rs1058808 (P1170A)<sup><a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338393">10</a>–<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338375">14</a></sup>. To be consistent with published associations of the I655V variant, we also performed genotypic analyses of the AG+GG genotypes versus the AA genotype on a case control basis, where cases were defined as a decrease of at least 10% points from baseline with a resulting LVEF of less than 50%, a decrease of 15% with respect to baseline, or any decrease resulting in LVEF less than 45% at least once during the treatment or clinical manifestation of CHF<sup><a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338386">14</a></sup>. We did not observe any association of the I655V or P1170A variants with either linear or logistic models (<a href="/pmc/articles/PMC5581215/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>SNPs previously associated with ERBB2 cardiotoxicity (Arms BC)</strong><p id="__p5">Association analyses were performed assuming an additive effect in both linear and logistic regression models. For logistic regression, we report genotype counts, odds ratio (OR) and P-values (P) using the more stringent definition of cases as per Gomez Pena et al, 2015: Decrease of at least 10% points from baseline with a resulting LVEF of less than 50% or decrease of 15% with respect to baseline, or any decrease resulting in LVEF less than 45% at least once during the treatment or clinical manifestation of CHF.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140277509646848" class="xtable"><table frame="box" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="bottom" align="left"></th><th rowspan="1" colspan="1" valign="bottom" align="left"></th><th colspan="2" rowspan="1" valign="bottom" align="center">Linear Max drop in LVEF</th><th colspan="4" rowspan="1" valign="bottom" align="center">Logistic LVEF literature</th></tr><tr><th rowspan="1" colspan="1" valign="bottom" align="left">SNP ID</th><th rowspan="1" colspan="1" valign="bottom" align="left">AA change</th><th rowspan="1" colspan="1" valign="bottom" align="left">Beta, L95-U95</th><th rowspan="1" colspan="1" valign="top" align="center">P</th><th rowspan="1" colspan="1" valign="bottom" align="left">genotype case</th><th rowspan="1" colspan="1" valign="bottom" align="left">genotype con</th><th rowspan="1" colspan="1" valign="bottom" align="left">OR, L95-U95</th><th rowspan="1" colspan="1" valign="bottom" align="center">P</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">rs1136201</td><td rowspan="1" colspan="1" valign="top" align="left">I655V</td><td rowspan="1" colspan="1" valign="top" align="left">−0.33 (−1.07 to 0.41)</td><td rowspan="1" colspan="1" valign="top" align="center">0.39</td><td rowspan="1" colspan="1" valign="top" align="left">GG=11</td><td rowspan="1" colspan="1" valign="top" align="left">GG=39</td><td rowspan="1" colspan="1" valign="top" align="left">0.941 (0.71 to 1.25)</td><td rowspan="1" colspan="1" valign="top" align="center">0.67</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="left">GA=59</td><td rowspan="1" colspan="1" valign="top" align="left">GA=228</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="left">AA=103</td><td rowspan="1" colspan="1" valign="top" align="left">AA=360</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs1058808</td><td rowspan="1" colspan="1" valign="top" align="left">P1170A</td><td rowspan="1" colspan="1" valign="top" align="left">−0.45 (−1.14 to 0.24)</td><td rowspan="1" colspan="1" valign="top" align="center">0.20</td><td rowspan="1" colspan="1" valign="top" align="left">CC=21</td><td rowspan="1" colspan="1" valign="top" align="left">CC=65</td><td rowspan="1" colspan="1" valign="top" align="left">1.034 (0.80 to 1.34)</td><td rowspan="1" colspan="1" valign="top" align="center">0.80</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="left">CG=78</td><td rowspan="1" colspan="1" valign="top" align="left">CG=293</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="left">GG=73</td><td rowspan="1" colspan="1" valign="top" align="left">GG=268</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr></tbody></table></div><div id="largeobj_idm140277509646848" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC5581215/table/T2/?report=objectonly">Open in a separate window</a></div></div><p id="P20" class="p p-last">We also assessed association at <em>ERBB2</em> by imputation including 200kb flanking region and linear regression of decline in LVEF, plotted in Locus Zoom (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure 4</a>) in those patients who received combination chemotherapy and trastuzumab (Arms BC). This analysis identified 95/943 SNPs at p&lt;0.05, although none of these remained significant following correction for multiple testing.</p></div><div id="S10" class="sec sec-last"><h3 id="S10title">Variants associated with anthracycline-induced cardiotoxicity</h3><p id="P21" class="p p-first-last">Several SNPs have been associated with anthracycline-induced cardiotoxicity<sup><a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338425">16</a>,<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338388">19</a>,<a href="#R20" rid="R20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338409">20</a>,<a href="#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338429">27</a>,<a href="#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338374">28</a></sup>. Under our linear model of decline in LVEF, we observed a significant association of the <em>CBR3</em> V244M variant in combined analyses of all patients (N=1,191), p=0.004, Beta=0.84 when A (Met) allele is reference<sup><a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338381">15</a>,<a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338426">16</a></sup>. We also observed association with the published <em>ABCB1</em> variant rs2235047 (p=0.018) and a trend for association of rs17863783 variant in <em>UGT1A6</em> (p=0.078). We also looked for enrichment of the associated allele in the subset of individuals with CHF (N=17). There was no evidence of enrichment at either the <em>CBR3</em> or <em>ABCB1</em> loci. However, we did observe enrichment of reported associated alleles at the <em>NCF4</em> and <em>RARG</em> loci in patients with CHF. Allele A of the NCF4 5′ flanking SNP, rs1883112, presented with a frequency of 0.44 in all patients who received chemotherapy (N=1,191) but only 0.24 (8/34 alleles) in patients with CHF, OR 0.35, p=0.011. The leucine allele of rs2229774 at the <em>RARG</em> locus was enriched in CHF patients relative to all patients who received chemotherapy (0.15 versus 0.07) and showed a trend for association, p=0.076. Locus zoom plots are shown in <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure 5</a>.</p></div></div><div id="S11" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S11title">Discussion</h2><p id="P22" class="p p-first">Cardiotoxicity is a major clinical side-effect of both anthracycline and trastuzumab therapy, with a higher incidence in patients receiving combination treatment compared to those receiving only anthracycline<sup><a href="#R25" rid="R25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338397">25</a>,<a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338406">29</a></sup>. The extent and frequency of cardiotoxicity is not uniform across patients, leading us to hypothesize a genetic influence. We performed a genome-wide association of decline in LVEF in patients treated with trastuzumab from the N9831 trial. This trial led to the use of trastuzumab as a standard of care in early onset HER2+ breast cancer. Our first approach used a quantitative analysis of the maximum observed decline in LVEF and DNA variants in patients from Arms BC (N=800) who received doxorubicin, paclitaxel and trastuzumab. We corrected for multiple testing with Benjamini-Hochberg and report those variants at q&lt;0.2 for a total of 23 variants (p&lt;1×10<sup>−5</sup>), from six novel loci: limb domain binding 2, (<em>LDB2</em>), an adapter molecule of transcriptional regulatory complexes<sup><a href="#R30" rid="R30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338392">30</a>,<a href="#R31" rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338396">31</a></sup>; BMP/retinoic acid-inducible neural-specific protein 1, (<em>BRINP1</em>), a suppressor of cell cycle progression<sup><a href="#R32" rid="R32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338403">32</a></sup>; transient receptor potential cation channel, subfamily C, member 6, (<em>TRPC6</em>), a central mediator of hypertrophic cardiomyopathy, cardiac remodeling<sup><a href="#R33" rid="R33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338421">33</a>–<a href="#R36" rid="R36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338379">36</a></sup>; a member of the RAS oncogene family, (<em>RAB22A</em>) involved in endocytic trafficking<sup><a href="#R37" rid="R37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338383">37</a>–<a href="#R39" rid="R39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338395">39</a></sup>; a LINC RNA, (LINC10160); and an intergenic region on chromosome 6.</p><p id="P23">Patients in Arms BC received both doxorubicin and trastuzumab. Therefore in an effort to discriminate between doxorubicin and trastuzumab-mediated cardiotoxicity, we reasoned that loci associated with decline in LVEF induced specifically by doxorubicin would be replicated in Arm A alone. However, none of the top variants were significant, p&lt;0.05, in the patients in Arm A (N=391) (<a href="/pmc/articles/PMC5581215/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). We did observe a trend for association of decline in LVEF for the intronic variant in <em>TRPC6</em> in patients who received chemotherapy only. This association was in the same direction and similar effect size as observed in patients receiving chemotherapy and trastuzumab, p=0.06 (1-tailed), suggesting that the <em>TRPC6</em> variant could be a result of chemotherapy. Evidence from the literature could support this hypothesis, because TRPC6 expression which is increased in cardiac tissue from patients with dilated cardiomyopathy<sup><a href="#R35" rid="R35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338428">35</a></sup> is also up-regulated by doxorubicin<sup><a href="#R40" rid="R40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338384">40</a></sup>. The failure to replicate other variants in patients in Arm A could infer that the novel associations in Arms BC are induced by combination chemotherapy and trastuzumab, although we acknowledge that Arm A (N=391) is smaller than Arms BC (N=800) and may lack statistical power to replicate. We do not believe associations in <a href="/pmc/articles/PMC5581215/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a> are a statistical artifact of different cumulative doses of doxorubicin as all patients in this analysis received the same dose (4 × 60 mg/m<sup>2</sup>) regimen completing chemotherapy with post-anthracycline LVEF remaining above 50% to continue with trastuzumab treatment.</p><p id="P24">To further discriminate between chemotherapy and trastuzumab-mediated cardiotoxicity, we also performed an exploratory analysis of each novel region. We hypothesized that true risk alleles of cardiotoxicity might be enriched in the subset of patients with CHF. At <em>LDB2</em>, <em>BRINP1</em> and <em>TRPC6</em> (low frequency variants, MAF&lt;0.02), we observed ≥ five-fold enrichment in the subset of patients with CHF who received trastuzumab (N=10). Interestingly, in those patients with CHF who received chemotherapy only (N=7) we did not observe any of the putative risk alleles at these loci, suggesting these associations may be trastuzumab-mediated with the caveat that our subset of patients with CHF is underpowered. In contrast, for the most common associated variants in <a href="/pmc/articles/PMC5581215/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>, chr6 intergenic region, <em>RAB22A</em> and <em>LINC01060</em>, we observed enrichment in those patients with CHF who received chemotherapy only (MAF 0.50, 0.57 and 0.36, respectively). We did not observe the same trend in the patients receiving trastuzumab who also developed CHF. If these variants are truly associated with doxorubicin and/or trastuzumab-mediated cardiotoxicity, one could hypothesize the existence of large effect size, low frequency variants that increase susceptibility to cardiotoxicity with combination chemotherapy and trastuzumab, and the existence of common cardiac risk variants that increase susceptibility to anthracycline-related cardiotoxicity.</p><p id="P25">Our GWAS data also included variants from the current literature that were reported to be associated with cardiotoxicity from either, trastuzumab, anthracycline or combination therapy. We failed to observe genome-wide significant association with any variant <em>ERBB2</em>, the target of trastuzumab. We did not observe any association at p&lt;0.05 for SNPs reported to be associated with trastuzumab-related cardiotoxicity in the current literature (i.e., rs1136201, I655V and rs1058808, P1170A). There are several possible reasons for this failure to replicate previous findings. We ruled out genotyping error based on concordant genotypes from multiple probes at rs1136201, genotypic data in Hardy-Weinberg equilibrium, observed allele frequencies in line with other reported studies and adequate cluster plots (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure 7</a>).</p><p id="P26">We next considered our definition of cardiotoxicity as a reason for lack of replication with <em>ERBB2</em> I655V and P1170A. Our primary analysis used a quantitative model of maximum decline in LVEF. Published associations used a binary definition of cardiotoxicity or no cardiotoxicity, but with different definitions in each case, including decrease in LVEF of at least 20% points<sup><a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338404">10</a></sup>; decrease in LVEF of at least 10% points to less than 50% or any decrease to &lt;45%<sup><a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338371">11</a></sup>; decrease &gt;10% points to &lt;50% or any decrease &gt;15% or any decrease resulting in &lt;45% or diagnosis of CHF<sup><a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338382">14</a></sup>. Hence we also looked for association with the same binary definition as Gomez Pena<sup><a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338418">14</a></sup>. Again, we did not observe any associations, p&lt;0.05. Acknowledging the caveat of the arbitrary definition of cardiotoxicity and the models we used, it is possible that our lack of replication was simply due to a smaller sample size in previous studies. Our data set from N9831 patients treated with trastuzumab (N=800) was over 2-fold greater compared to the four published studies combined (N=344, ranging 61–132 patients<sup><a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338405">14</a></sup>), which showed large odds ratios ranging from 3.80 to 5.80. We note that there are no published negative studies of these variants with cardiotoxicity, which may suggest a publication bias towards positive associations in when using small sample sizes.</p><p id="P27">Our analysis of published SNPs associated with anthracycline cardiotoxicity in all patients who received doxorubicin (Arms A, B and C combined, N=1,191) was more successful in that we did observe association of the <em>CBR3</em> V244M variant in our quantitative analysis of maximum decline in LVEF (p=0.004) with supporting evidence from multiple SNPs at this locus. Carbonyl reductases (CBRs) catalyze reduction of anthracyclines to cardiotoxic alcohol metabolites and polymorphisms in <em>CBR1</em> and <em>CBR3</em> influence the synthesis of these metabolites. <em>CBR3</em> V244M was previously associated with a dose-dependent risk of anthracycline-related cardiomyopathy in childhood cancer survivors<sup><a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338402">15</a></sup>, and with cardiotoxicity in a cohort of breast cancer patients<sup><a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338410">16</a></sup>. In a literature review entitled, ‘Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity’ it was deemed that <em>CBR3</em> required further validation. Our study confirms association of this variant in patients with breast cancer.</p><p id="P28">Similarly, we observed association of a variant in <em>ABCB1</em>, rs2235047, also previously associated with anthracycline-induced cardiotoxicity in children, where 266 were controls (defined as systolic function &gt;30% during and after therapy, with follow-up of more than five years after completion of anthracycline therapy) and 78 cases (defined as systolic function ≤26% at any time during or after anthracycline therapy)<sup><a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338430">19</a></sup>. This variant was not confirmed in a further study of children, consisting of 46 cases and 131 controls, analysed with the same methodology from the same group<sup><a href="#R20" rid="R20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338373">20</a></sup>, perhaps due to lack of power. However, in this study we observed an association of similar magnitiude (Beta = −2.34, p=0.018) in our linear model of decline in LVEF in 1,191 patients receiving doxorubicin, adding further evidence for this association. Certainly, this gene is a reasonable candidate due to its involvement in drug excretion in the kidney, liver, and heart<sup><a href="#R41" rid="R41" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338387">41</a>,<a href="#R42" rid="R42" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338394">42</a></sup>. Specifically, changes in <em>ABCB1</em> expression or function prolong the presence of both doxorubicin in cardiac tissue and its cardiotoxic metabolite, doxorubicinol, within cardiac tissue<sup><a href="#R43" rid="R43" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338423">43</a></sup>. Furthermore, the ERBB2 inhibitor, lapatinib, has been shown to inhibit the function of <em>ABCB1</em><sup><a href="#R44" rid="R44" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338380">44</a></sup>, suggesting a possible mechanism for increased cardiotoxicity as a result of doxorubicin in combination with HER2 targeted therapy.</p><p id="P29">We did not observe an association of published SNPs associated with doxorubicin-induced cardiotoxicity in <em>SLC28A3</em>, <em>NCF4</em>, <em>RAC2</em>, <em>RARG</em> and <em>UGT1A6</em> in our linear model of decline in LVEF in 1,191 patients receiving doxorubicin (<a href="/pmc/articles/PMC5581215/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). Given these were associations with CHF rather than decline in LVEF, we also tested for these variants in the limited subset of patients (N=17) with CHF. Aminkeng et al<sup><a href="#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338431">28</a></sup> reported a highly signficant association of the 427Leu variant within retinoic acid receptor γ, <em>RARG</em> (rs2229774, Ser427Leu) with CHF in three studies of children (cases N=32, N=22 and N=19, respectively) treated with anthracyclines (either doxorubicin, daunorubicin, idarubicin, epirubicin or mitoxantrone). In our smaller subset of CHF patients from the N9831 trial treated with doxorubicin, we observed a weak association of the 427Leu variant, OR=2.39, p=0.038 (1-tailed). We also observed association of the <em>NCF4</em> rs1883112 A allele, OR 0.35, p=0.01 (2-tailed) (A allele frequency in CHF patients = 0.24 vs 0.44 in patients who were not confirmed with CHF). However, our finding is in the opposite direction to other reported associations. The AA genotype of this variant was previously associated with CHF in adult non-Hodgkin lymphoma patients treated with doxorubicin, OR 2.00, p=0.018<sup><a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338417">18</a></sup> and the A allele was associated with CHF in cancer patients treated with anthracyclines, OR 5.11, p=0.016<sup><a href="#R45" rid="R45" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338372">45</a></sup>.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>SNPs previously associated with anthracycline cardiotoxicity (Arms ABC)</strong><p id="__p6">Additive effect linear regression analyses in all Arms combined. Logistic regression was performed in those cases (N=17) with congestive heart failure (CHF) versus all other patients. P-values &lt;0.05 are highlighted in bold.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140277501381152" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="bottom" align="left"></th><th rowspan="1" colspan="1" valign="bottom" align="left"></th><th rowspan="1" colspan="1" valign="bottom" align="left"></th><th colspan="3" rowspan="1" valign="bottom" align="center">Linear Max drop in LVEF</th><th colspan="3" rowspan="1" valign="bottom" align="left">Logistic CHF (N=17)</th></tr><tr><th rowspan="1" colspan="1" valign="bottom" align="left">Gene</th><th rowspan="1" colspan="1" valign="bottom" align="left">rs ID</th><th rowspan="1" colspan="1" valign="bottom" align="left">Function</th><th rowspan="1" colspan="1" valign="bottom" align="center">Freq A1 (N=1191)</th><th rowspan="1" colspan="1" valign="bottom" align="left">Beta, L95-U95</th><th rowspan="1" colspan="1" valign="bottom" align="center">P</th><th rowspan="1" colspan="1" valign="bottom" align="center">Freq A1 (N=17)</th><th rowspan="1" colspan="1" valign="bottom" align="left">OR, L95-U95</th><th rowspan="1" colspan="1" valign="bottom" align="center">P</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="bottom" align="left">ABCB1</td><td rowspan="1" colspan="1" valign="bottom" align="left">rs2235047</td><td rowspan="1" colspan="1" valign="bottom" align="left">intronic</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.02</td><td rowspan="1" colspan="1" valign="bottom" align="left">−2.34 (−4.28 to −0.40)</td><td rowspan="1" colspan="1" valign="bottom" align="center"><strong>0.018</strong></td><td rowspan="1" colspan="1" valign="bottom" align="center">0.00</td><td rowspan="1" colspan="1" valign="bottom" align="left">NA</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.996</td></tr><tr><td rowspan="1" colspan="1" valign="bottom" align="left">SLC28A3</td><td rowspan="1" colspan="1" valign="bottom" align="left">rs7853758</td><td rowspan="1" colspan="1" valign="bottom" align="left">L464L</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.16</td><td rowspan="1" colspan="1" valign="bottom" align="left">−0.11 (−0.84 to 0.62)</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.766</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.12</td><td rowspan="1" colspan="1" valign="bottom" align="left">0.71 (0.25 to 2.02)</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.523</td></tr><tr><td rowspan="1" colspan="1" valign="bottom" align="left">CBR3</td><td rowspan="1" colspan="1" valign="bottom" align="left">rs1056892</td><td rowspan="1" colspan="1" valign="bottom" align="left">V244M</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.35</td><td rowspan="1" colspan="1" valign="bottom" align="left">0.84 (0.26 to 1.41)</td><td rowspan="1" colspan="1" valign="bottom" align="center"><strong>0.004</strong></td><td rowspan="1" colspan="1" valign="bottom" align="center">0.35</td><td rowspan="1" colspan="1" valign="bottom" align="left">1.01 (0.49 to 2.08)</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.972</td></tr><tr><td rowspan="1" colspan="1" valign="bottom" align="left">NCF4</td><td rowspan="1" colspan="1" valign="bottom" align="left">rs1883112</td><td rowspan="1" colspan="1" valign="bottom" align="left">5′ flanking</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.44</td><td rowspan="1" colspan="1" valign="bottom" align="left">0.19 (−0.36 to 0.72)</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.492</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.24</td><td rowspan="1" colspan="1" valign="bottom" align="left">0.35 (0.15 to 0.78)</td><td rowspan="1" colspan="1" valign="bottom" align="center"><strong>0.011</strong></td></tr><tr><td rowspan="1" colspan="1" valign="bottom" align="left">RAC2</td><td rowspan="1" colspan="1" valign="bottom" align="left">rs13058338</td><td rowspan="1" colspan="1" valign="bottom" align="left">intronic</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.26</td><td rowspan="1" colspan="1" valign="bottom" align="left">0.05 (−0.55 to 0.66)</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.861</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.29</td><td rowspan="1" colspan="1" valign="bottom" align="left">1.21 (0.58 to 2.57)</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.611</td></tr><tr><td rowspan="1" colspan="1" valign="bottom" align="left">RARG</td><td rowspan="1" colspan="1" valign="bottom" align="left">rs2229774</td><td rowspan="1" colspan="1" valign="bottom" align="left">S427L</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.07</td><td rowspan="1" colspan="1" valign="bottom" align="left">0.44 (0.61 to 1.48)</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.412</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.15</td><td rowspan="1" colspan="1" valign="bottom" align="left">2.39 (0.91 to 6.23)</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.076</td></tr><tr><td rowspan="1" colspan="1" valign="bottom" align="left">UGT1A6</td><td rowspan="1" colspan="1" valign="bottom" align="left">rs17863783</td><td rowspan="1" colspan="1" valign="bottom" align="left">V209V</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.02</td><td rowspan="1" colspan="1" valign="bottom" align="left">−1.67 (−3.52 to 0.18)</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.078</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.00</td><td rowspan="1" colspan="1" valign="bottom" align="left">NA</td><td rowspan="1" colspan="1" valign="bottom" align="center">0.996</td></tr></tbody></table></div><div id="largeobj_idm140277501381152" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC5581215/table/T3/?report=objectonly">Open in a separate window</a></div></div><p id="P30">A weakness of our study is the inability to validate our finidngs using other methods. Recognizing this weakness, we scanned the literature for reported cardiac modifying genes in animal models. This led us to examine four genes (<em>SORBS2</em>, <em>RXRA</em>, <em>DNAJB6</em> and <em>ANO5</em>) reported as cardiac modifiers of doxorubicin-induced cardiotoxicity in zebrafish and/or mouse models<sup><a href="#R46" rid="R46" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_635338427">46</a>,<a href="#R47" rid="R47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_636172235">47</a></sup>. Suggesting that our data can be replicated we also identified variants in our study of N9831 in <em>SORBS2</em> and <em>RXRA</em> and p&lt;0.01 in <em>DNAJB6</em>, p&lt;0.001 (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Table 3</a>). These finidngs suggest that these genes require further study as genes modified by chemotherapy treatments that could increase the risk for cardiomyopathy in patients.</p><p id="P31" class="p p-last">In summary, our study confirmed previously reported associations of chemotherapy-induced cardiotoxicity with variants in the <em>ABCB1</em> and <em>CBR3</em> genes. We failed to replicate previous findings at <em>ERBB2</em> with any model of cardiotoxicity (linear or logistic); however, our sample size was significantly larger than other published studies suggesting that previous associations may have occurred due to small sample size. In an effort to identify novel loci relevant to patients receiving combination chemotherapy and trastuzumab, we identified six potential susceptibility loci. Further study is needed to confirm the role of these loci in trastuzumab-induced cardiomyopathy.</p></div><div id="S12" class="tsec sec"><a id="supplementary-material-sec"></a><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S12title">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>Supplemental Digital Content_clean</h4><div class="sup-box half_rhythm" id="d36e952"><a href="/pmc/articles/PMC5581215/bin/NIHMS892344-supplement-Supplemental_Digital_Content_clean.docx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(1.7M, docx)</sup></div></div></div><div id="S13" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S13title">Acknowledgments</h2><div class="sec"><p id="__p1"><strong>Funding Sources.</strong> This work was supported by The Mackenzie Foundation, Breast Cancer Research Foundation, and a Gerstner Career Development Award to NN and National Institutes of Health (R01 HL111938, R21 ES024414) and American Heart Association (16GRNT30950007) grants to DF.</p></div></div><div id="idm140277501071072" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140277501071072title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN2"></p><p id="__p2" class="p p-first-last"><strong>Conflicts of Interest:</strong> None declared</p><p></p></div></div><div id="idm140277499928736" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140277499928736title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="element-citation">Narahara KA, Singer JW, Ritchie JL, Williams DL, Hamilton GW, Kennedy JW. Time- and dose-dependent changes in ejection fraction after anthracycline therapy. <span><span class="ref-journal">J Cardiovasc Pharmacol. </span>1979 Jul-Aug;<span class="ref-vol">1</span>(4):395–401.</span> [<a href="/pubmed/94617" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Cardiovasc+Pharmacol&amp;title=Time-+and+dose-dependent+changes+in+ejection+fraction+after+anthracycline+therapy&amp;author=KA+Narahara&amp;author=JW+Singer&amp;author=JL+Ritchie&amp;author=DL+Williams&amp;author=GW+Hamilton&amp;volume=1&amp;issue=4&amp;publication_year=1979&amp;pages=395-401&amp;pmid=94617&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="element-citation">Advani P, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial. <span><span class="ref-journal">Journal of Clinical Oncology. </span>2014;<span class="ref-vol">32</span>(15S):30s.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Oncology&amp;title=Long-term+cardiac+safety+analysis+of+NCCTG+(Alliance)+N9831+adjuvant+trastuzumab+(H)+trial&amp;author=P+Advani&amp;author=KV+Ballman&amp;author=TJ+Dockter&amp;author=G+Colon-Otero&amp;author=EA+Perez&amp;volume=32&amp;issue=15S&amp;publication_year=2014&amp;pages=30s&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="element-citation">Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J, Jr, Chien KR, Lee KF. ErbB2 is essential in the prevention of dilated cardiomyopathy. <span><span class="ref-journal">Nat Med. </span>2002 May;<span class="ref-vol">8</span>(5):459–465.</span> [<a href="/pubmed/11984589" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=ErbB2+is+essential+in+the+prevention+of+dilated+cardiomyopathy&amp;author=SA+Crone&amp;author=YY+Zhao&amp;author=L+Fan&amp;author=Y+Gu&amp;author=S+Minamisawa&amp;volume=8&amp;issue=5&amp;publication_year=2002&amp;pages=459-465&amp;pmid=11984589&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="element-citation">Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. <span><span class="ref-journal">Recent Prog Horm Res. </span>2004;<span class="ref-vol">59</span>:1–12.</span> [<a href="/pubmed/14749494" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Recent+Prog+Horm+Res&amp;title=Essential+roles+of+Her2/erbB2+in+cardiac+development+and+function&amp;author=A+Negro&amp;author=BK+Brar&amp;author=KF+Lee&amp;volume=59&amp;publication_year=2004&amp;pages=1-12&amp;pmid=14749494&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="element-citation">Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. <span><span class="ref-journal">Nat Rev Cardiol. </span>2013 Sep;<span class="ref-vol">10</span>(9):531–547.</span> [<a href="/pubmed/23900355" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cardiol&amp;title=Dilated+cardiomyopathy:+the+complexity+of+a+diverse+genetic+architecture&amp;author=RE+Hershberger&amp;author=DJ+Hedges&amp;author=A+Morales&amp;volume=10&amp;issue=9&amp;publication_year=2013&amp;pages=531-547&amp;pmid=23900355&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="element-citation">Norton N, Robertson PD, Rieder MJ, Zuchner S, Rampersaud E, Martin E, Li D, Nickerson DA, Hershberger RE. Evaluating pathogenicity of rare variants from dilated cardiomyopathy in the exome era. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2012 Apr 1;<span class="ref-vol">5</span>(2):167–174.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3332064/">PMC free article</a>]</span> [<a href="/pubmed/22337857" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Circ+Cardiovasc+Genet&amp;title=Evaluating+pathogenicity+of+rare+variants+from+dilated+cardiomyopathy+in+the+exome+era&amp;author=N+Norton&amp;author=PD+Robertson&amp;author=MJ+Rieder&amp;author=S+Zuchner&amp;author=E+Rampersaud&amp;volume=5&amp;issue=2&amp;publication_year=2012&amp;pages=167-174&amp;pmid=22337857&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="element-citation">Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, Conner L, DePalma SR, McDonough B, Sparks E, Teodorescu DL, Cirino AL, Banner NR, Pennell DJ, Graw S, Merlo M, Di Lenarda A, Sinagra G, Bos JM, Ackerman MJ, Mitchell RN, Murry CE, Lakdawala NK, Ho CY, Barton PJ, Cook SA, Mestroni L, Seidman JG, Seidman CE. Truncations of titin causing dilated cardiomyopathy. <span><span class="ref-journal">N Engl J Med. </span>2012 Feb 16;<span class="ref-vol">366</span>(7):619–628.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3660031/">PMC free article</a>]</span> [<a href="/pubmed/22335739" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Truncations+of+titin+causing+dilated+cardiomyopathy&amp;author=DS+Herman&amp;author=L+Lam&amp;author=MR+Taylor&amp;author=L+Wang&amp;author=P+Teekakirikul&amp;volume=366&amp;issue=7&amp;publication_year=2012&amp;pages=619-628&amp;pmid=22335739&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="element-citation">Rampersaud E, Kinnamon DD, Hamilton K, Khuri S, Hershberger RE, Martin ER. Common susceptibility variants examined for association with dilated cardiomyopathy. <span><span class="ref-journal">Ann Hum Genet. </span>2010 Mar;<span class="ref-vol">74</span>(2):110–116.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2866200/">PMC free article</a>]</span> [<a href="/pubmed/20201937" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Hum+Genet&amp;title=Common+susceptibility+variants+examined+for+association+with+dilated+cardiomyopathy&amp;author=E+Rampersaud&amp;author=DD+Kinnamon&amp;author=K+Hamilton&amp;author=S+Khuri&amp;author=RE+Hershberger&amp;volume=74&amp;issue=2&amp;publication_year=2010&amp;pages=110-116&amp;pmid=20201937&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="element-citation">Villard E, Perret C, Gary F, Proust C, Dilanian G, Hengstenberg C, Ruppert V, Arbustini E, Wichter T, Germain M, Dubourg O, Tavazzi L, Aumont MC, DeGroote P, Fauchier L, Trochu JN, Gibelin P, Aupetit JF, Stark K, Erdmann J, Hetzer R, Roberts AM, Barton PJ, Regitz-Zagrosek V, Aslam U, Duboscq-Bidot L, Meyborg M, Maisch B, Madeira H, Waldenstrom A, Galve E, Cleland JG, Dorent R, Roizes G, Zeller T, Blankenberg S, Goodall AH, Cook S, Tregouet DA, Tiret L, Isnard R, Komajda M, Charron P, Cambien F. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. <span><span class="ref-journal">Eur Heart J. </span>2011 May;<span class="ref-vol">32</span>(9):1065–1076.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3086901/">PMC free article</a>]</span> [<a href="/pubmed/21459883" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+Heart+J&amp;title=A+genome-wide+association+study+identifies+two+loci+associated+with+heart+failure+due+to+dilated+cardiomyopathy&amp;author=E+Villard&amp;author=C+Perret&amp;author=F+Gary&amp;author=C+Proust&amp;author=G+Dilanian&amp;volume=32&amp;issue=9&amp;publication_year=2011&amp;pages=1065-1076&amp;pmid=21459883&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="element-citation">Beauclair S, Formento P, Fischel JL, Lescaut W, Largillier R, Chamorey E, Hofman P, Ferrero JM, Pages G, Milano G. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. <span><span class="ref-journal">Ann Oncol. </span>2007 Aug;<span class="ref-vol">18</span>(8):1335–1341.</span> [<a href="/pubmed/17693647" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Oncol&amp;title=Role+of+the+HER2+[Ile655Val]+genetic+polymorphism+in+tumorogenesis+and+in+the+risk+of+trastuzumab-related+cardiotoxicity&amp;author=S+Beauclair&amp;author=P+Formento&amp;author=JL+Fischel&amp;author=W+Lescaut&amp;author=R+Largillier&amp;volume=18&amp;issue=8&amp;publication_year=2007&amp;pages=1335-1341&amp;pmid=17693647&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="element-citation">Lemieux J, Diorio C, Cote MA, Provencher L, Barabe F, Jacob S, St-Pierre C, Demers E, Tremblay-Lemay R, Nadeau-Larochelle C, Michaud A, Laflamme C. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. <span><span class="ref-journal">Anticancer Res. </span>2013 Jun;<span class="ref-vol">33</span>(6):2569–2576.</span> [<a href="/pubmed/23749910" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Anticancer+Res&amp;title=Alcohol+and+HER2+polymorphisms+as+risk+factor+for+cardiotoxicity+in+breast+cancer+treated+with+trastuzumab&amp;author=J+Lemieux&amp;author=C+Diorio&amp;author=MA+Cote&amp;author=L+Provencher&amp;author=F+Barabe&amp;volume=33&amp;issue=6&amp;publication_year=2013&amp;pages=2569-2576&amp;pmid=23749910&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="element-citation">Roca L, Dieras V, Roche H, Lappartient E, Kerbrat P, Cany L, Chieze S, Canon JL, Spielmann M, Penault-Llorca F, Martin AL, Mesleard C, Lemonnier J, de Cremoux P. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2013 Jun;<span class="ref-vol">139</span>(3):789–800.</span> [<a href="/pubmed/23780683" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+Treat&amp;title=Correlation+of+HER2,+FCGR2A,+and+FCGR3A+gene+polymorphisms+with+trastuzumab+related+cardiac+toxicity+and+efficacy+in+a+subgroup+of+patients+from+UNICANCER-PACS+04+trial&amp;author=L+Roca&amp;author=V+Dieras&amp;author=H+Roche&amp;author=E+Lappartient&amp;author=P+Kerbrat&amp;volume=139&amp;issue=3&amp;publication_year=2013&amp;pages=789-800&amp;pmid=23780683&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="element-citation">Stanton SE, Ward MM, Christos P, Sanford R, Lam C, Cobham MV, Donovan D, Scheff RJ, Cigler T, Moore A, Vahdat LT, Lane ME, Chuang E. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. <span><span class="ref-journal">BMC Cancer. </span>2015;<span class="ref-vol">15</span>:267.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4403678/">PMC free article</a>]</span> [<a href="/pubmed/25885598" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMC+Cancer&amp;title=Pro1170+Ala+polymorphism+in+HER2-neu+is+associated+with+risk+of+trastuzumab+cardiotoxicity&amp;author=SE+Stanton&amp;author=MM+Ward&amp;author=P+Christos&amp;author=R+Sanford&amp;author=C+Lam&amp;volume=15&amp;publication_year=2015&amp;pages=267&amp;pmid=25885598&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="element-citation">Gomez Pena C, Davila-Fajardo CL, Martinez-Gonzalez LJ, Carmona-Saez P, Soto Pino MJ, Sanchez Ramos J, Moreno Escobar E, Blancas I, Fernandez JJ, Fernandez D, Correa C, Cabeza Barrera J. Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis. <span><span class="ref-journal">Pharmacogenet Genomics. </span>2015 Aug;<span class="ref-vol">25</span>(8):388–393.</span> [<a href="/pubmed/26049584" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenet+Genomics&amp;title=Influence+of+the+HER2+Ile655Val+polymorphism+on+trastuzumab-induced+cardiotoxicity+in+HER2-positive+breast+cancer+patients:+a+meta-analysis&amp;author=C+Gomez+Pena&amp;author=CL+Davila-Fajardo&amp;author=LJ+Martinez-Gonzalez&amp;author=P+Carmona-Saez&amp;author=MJ+Soto+Pino&amp;volume=25&amp;issue=8&amp;publication_year=2015&amp;pages=388-393&amp;pmid=26049584&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="element-citation">Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes–a report from the Children’s Oncology Group. <span><span class="ref-journal">Journal of clinical oncology: official journal of the American Society of Clinical Oncology. </span>2012 May 1;<span class="ref-vol">30</span>(13):1415–1421.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3383117/">PMC free article</a>]</span> [<a href="/pubmed/22124095" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+clinical+oncology:+official+journal+of+the+American+Society+of+Clinical+Oncology&amp;title=Anthracycline-related+cardiomyopathy+after+childhood+cancer:+role+of+polymorphisms+in+carbonyl+reductase+genes–a+report+from+the+Children’s+Oncology+Group&amp;author=JG+Blanco&amp;author=CL+Sun&amp;author=W+Landier&amp;author=L+Chen&amp;author=D+Esparza-Duran&amp;volume=30&amp;issue=13&amp;publication_year=2012&amp;pages=1415-1421&amp;pmid=22124095&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="element-citation">Hertz DL, Caram MV, Kidwell KM, Thibert JN, Gersch C, Seewald NJ, Smerage J, Rubenfire M, Henry NL, Cooney KA, Leja M, Griggs JJ, Rae JM. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. <span><span class="ref-journal">Pharmacogenomics. </span>2016 Feb;<span class="ref-vol">17</span>(3):231–240.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5558515/">PMC free article</a>]</span> [<a href="/pubmed/26799497" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics&amp;title=Evidence+for+association+of+SNPs+in+ABCB1+and+CBR3,+but+not+RAC2,+NCF4,+SLC28A3+or+TOP2B,+with+chronic+cardiotoxicity+in+a+cohort+of+breast+cancer+patients+treated+with+anthracyclines&amp;author=DL+Hertz&amp;author=MV+Caram&amp;author=KM+Kidwell&amp;author=JN+Thibert&amp;author=C+Gersch&amp;volume=17&amp;issue=3&amp;publication_year=2016&amp;pages=231-240&amp;pmid=26799497&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="element-citation">Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, De Paoli L, Ramponi A, Chiappella A, Pogliani EM, Vitolo U, Kwee I, Bertoni F, Conconi A, Gaidano G. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. <span><span class="ref-journal">Leukemia. </span>2009 Jun;<span class="ref-vol">23</span>(6):1118–1126.</span> [<a href="/pubmed/19448608" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Analysis+of+the+host+pharmacogenetic+background+for+prediction+of+outcome+and+toxicity+in+diffuse+large+B-cell+lymphoma+treated+with+R-CHOP21&amp;author=D+Rossi&amp;author=S+Rasi&amp;author=S+Franceschetti&amp;author=D+Capello&amp;author=A+Castelli&amp;volume=23&amp;issue=6&amp;publication_year=2009&amp;pages=1118-1126&amp;pmid=19448608&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="element-citation">Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, Vonhof S, Bickeboller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nurnberg P, Pfreundschuh M, Trumper L, Brockmoller J, Hasenfuss G. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. <span><span class="ref-journal">Circulation. </span>2005 Dec 13;<span class="ref-vol">112</span>(24):3754–3762.</span> [<a href="/pubmed/16330681" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=NAD(P)H+oxidase+and+multidrug+resistance+protein+genetic+polymorphisms+are+associated+with+doxorubicin-induced+cardiotoxicity&amp;author=L+Wojnowski&amp;author=B+Kulle&amp;author=M+Schirmer&amp;author=G+Schluter&amp;author=A+Schmidt&amp;volume=112&amp;issue=24&amp;publication_year=2005&amp;pages=3754-3762&amp;pmid=16330681&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="element-citation">Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dube MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. <span><span class="ref-journal">Journal of clinical oncology: official journal of the American Society of Clinical Oncology. </span>2012 May 1;<span class="ref-vol">30</span>(13):1422–1428.</span> [<a href="/pubmed/21900104" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+clinical+oncology:+official+journal+of+the+American+Society+of+Clinical+Oncology&amp;title=Pharmacogenomic+prediction+of+anthracycline-induced+cardiotoxicity+in+children&amp;author=H+Visscher&amp;author=CJ+Ross&amp;author=SR+Rassekh&amp;author=A+Barhdadi&amp;author=MP+Dube&amp;volume=30&amp;issue=13&amp;publication_year=2012&amp;pages=1422-1428&amp;pmid=21900104&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="element-citation">Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2013 Aug;<span class="ref-vol">60</span>(8):1375–1381.</span> [<a href="/pubmed/23441093" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pediatr+Blood+Cancer&amp;title=Validation+of+variants+in+SLC28A3+and+UGT1A6+as+genetic+markers+predictive+of+anthracycline-induced+cardiotoxicity+in+children&amp;author=H+Visscher&amp;author=CJ+Ross&amp;author=SR+Rassekh&amp;author=GS+Sandor&amp;author=HN+Caron&amp;volume=60&amp;issue=8&amp;publication_year=2013&amp;pages=1375-1381&amp;pmid=23441093&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="element-citation">Perez EA. Cardiac toxicity of ErbB2-targeted therapies: What do we know? <span><span class="ref-journal">Clin Breast Cancer. </span>2008 Mar;<span class="ref-vol">8</span>:S114–S120.</span> [<a href="/pubmed/18777950" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Breast+Cancer&amp;title=Cardiac+toxicity+of+ErbB2-targeted+therapies:+What+do+we+know?&amp;author=EA+Perez&amp;volume=8&amp;publication_year=2008&amp;pages=S114-S120&amp;pmid=18777950&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="element-citation">Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. <span><span class="ref-journal">J Clin Oncol. </span>2010 Jul 20;<span class="ref-vol">28</span>(21):3422–3428.</span> [<a href="/pubmed/20530280" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Longer-term+assessment+of+trastuzumab-related+cardiac+adverse+events+in+the+Herceptin+Adjuvant+(HERA)+trial&amp;author=M+Procter&amp;author=TM+Suter&amp;author=E+de+Azambuja&amp;author=U+Dafni&amp;author=V+van+Dooren&amp;volume=28&amp;issue=21&amp;publication_year=2010&amp;pages=3422-3428&amp;pmid=20530280&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="element-citation">Wang SY, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP, Chen J. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2014 Jun 21;</span> [<a href="/pubmed/24951268" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+Treat&amp;title=Cardiovascular+events,+early+discontinuation+of+trastuzumab,+and+their+impact+on+survival&amp;author=SY+Wang&amp;author=JB+Long&amp;author=A+Hurria&amp;author=C+Owusu&amp;author=RM+Steingart&amp;publication_year=2014&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="element-citation">Bernaba BN, Chan JB, Lai CK, Fishbein MC. Pathology of late-onset anthracycline cardiomyopathy. <span><span class="ref-journal">Cardiovasc Pathol. </span>2010 Sep-Oct;<span class="ref-vol">19</span>(5):308–311.</span> [<a href="/pubmed/19747852" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc+Pathol&amp;title=Pathology+of+late-onset+anthracycline+cardiomyopathy&amp;author=BN+Bernaba&amp;author=JB+Chan&amp;author=CK+Lai&amp;author=MC+Fishbein&amp;volume=19&amp;issue=5&amp;publication_year=2010&amp;pages=308-311&amp;pmid=19747852&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="element-citation">Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. <span><span class="ref-journal">Journal of clinical oncology: official journal of the American Society of Clinical Oncology. </span>2016 Feb 20;<span class="ref-vol">34</span>(6):581–587.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4980566/">PMC free article</a>]</span> [<a href="/pubmed/26392097" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+clinical+oncology:+official+journal+of+the+American+Society+of+Clinical+Oncology&amp;title=Long-Term+Cardiac+Safety+Analysis+of+NCCTG+N9831+(Alliance)+Adjuvant+Trastuzumab+Trial&amp;author=PP+Advani&amp;author=KV+Ballman&amp;author=TJ+Dockter&amp;author=G+Colon-Otero&amp;author=EA+Perez&amp;volume=34&amp;issue=6&amp;publication_year=2016&amp;pages=581-587&amp;pmid=26392097&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="element-citation">Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer CJ. LocusZoom: regional visualization of genome-wide association scan results. <span><span class="ref-journal">Bioinformatics. </span>2010 Sep 15;<span class="ref-vol">26</span>(18):2336–2337.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2935401/">PMC free article</a>]</span> [<a href="/pubmed/20634204" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioinformatics&amp;title=LocusZoom:+regional+visualization+of+genome-wide+association+scan+results&amp;author=RJ+Pruim&amp;author=RP+Welch&amp;author=S+Sanna&amp;author=TM+Teslovich&amp;author=PS+Chines&amp;volume=26&amp;issue=18&amp;publication_year=2010&amp;pages=2336-2337&amp;pmid=20634204&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="element-citation">Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, Smith A, Sanatani S, Gelmon KA, Bernstein D, Hayden MR, Amstutz U, Carleton BC. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2016 Sep;<span class="ref-vol">82</span>(3):683–695.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5338111/">PMC free article</a>]</span> [<a href="/pubmed/27197003" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Clin+Pharmacol&amp;title=Recommendations+for+genetic+testing+to+reduce+the+incidence+of+anthracycline-induced+cardiotoxicity&amp;author=F+Aminkeng&amp;author=CJ+Ross&amp;author=SR+Rassekh&amp;author=S+Hwang&amp;author=MJ+Rieder&amp;volume=82&amp;issue=3&amp;publication_year=2016&amp;pages=683-695&amp;pmid=27197003&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="element-citation">Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJ. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. <span><span class="ref-journal">Nature genetics. </span>2015 Sep;<span class="ref-vol">47</span>(9):1079–1084.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4552570/">PMC free article</a>]</span> [<a href="/pubmed/26237429" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+genetics&amp;title=A+coding+variant+in+RARG+confers+susceptibility+to+anthracycline-induced+cardiotoxicity+in+childhood+cancer&amp;author=F+Aminkeng&amp;author=AP+Bhavsar&amp;author=H+Visscher&amp;author=SR+Rassekh&amp;author=Y+Li&amp;volume=47&amp;issue=9&amp;publication_year=2015&amp;pages=1079-1084&amp;pmid=26237429&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="element-citation">Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. <span><span class="ref-journal">New Engl J Med. </span>2001 Mar 15;<span class="ref-vol">344</span>(11):783–792.</span> [<a href="/pubmed/11248153" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=New+Engl+J+Med&amp;title=Use+of+chemotherapy+plus+a+monoclonal+antibody+against+HER2+for+metastatic+breast+cancer+that+overexpresses+HER2&amp;author=DJ+Slamon&amp;author=B+Leyland-Jones&amp;author=S+Shak&amp;author=H+Fuchs&amp;author=V+Paton&amp;volume=344&amp;issue=11&amp;publication_year=2001&amp;pages=783-792&amp;pmid=11248153&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="element-citation">Agulnick AD, Taira M, Breen JJ, Tanaka T, Dawid IB, Westphal H. Interactions of the LIM-domain-binding factor Ldb1 with LIM homeodomain proteins. <span><span class="ref-journal">Nature. </span>1996 Nov 21;<span class="ref-vol">384</span>(6606):270–272.</span> [<a href="/pubmed/8918878" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Interactions+of+the+LIM-domain-binding+factor+Ldb1+with+LIM+homeodomain+proteins&amp;author=AD+Agulnick&amp;author=M+Taira&amp;author=JJ+Breen&amp;author=T+Tanaka&amp;author=IB+Dawid&amp;volume=384&amp;issue=6606&amp;publication_year=1996&amp;pages=270-272&amp;pmid=8918878&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="element-citation">Jurata LW, Gill GN. Functional analysis of the nuclear LIM domain interactor NLI. <span><span class="ref-journal">Molecular and cellular biology. </span>1997 Oct;<span class="ref-vol">17</span>(10):5688–5698.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC232417/">PMC free article</a>]</span> [<a href="/pubmed/9315627" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Molecular+and+cellular+biology&amp;title=Functional+analysis+of+the+nuclear+LIM+domain+interactor+NLI&amp;author=LW+Jurata&amp;author=GN+Gill&amp;volume=17&amp;issue=10&amp;publication_year=1997&amp;pages=5688-5698&amp;pmid=9315627&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span class="element-citation">Kawano H, Nakatani T, Mori T, Ueno S, Fukaya M, Abe A, Kobayashi M, Toda F, Watanabe M, Matsuoka I. Identification and characterization of novel developmentally regulated neural-specific proteins, BRINP family. <span><span class="ref-journal">Brain research Molecular brain research. </span>2004 Jun 18;<span class="ref-vol">125</span>(1–2):60–75.</span> [<a href="/pubmed/15193423" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Brain+research+Molecular+brain+research&amp;title=Identification+and+characterization+of+novel+developmentally+regulated+neural-specific+proteins,+BRINP+family&amp;author=H+Kawano&amp;author=T+Nakatani&amp;author=T+Mori&amp;author=S+Ueno&amp;author=M+Fukaya&amp;volume=125&amp;issue=1–2&amp;publication_year=2004&amp;pages=60-75&amp;pmid=15193423&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">33. <span class="element-citation">Eder P, Molkentin JD. TRPC channels as effectors of cardiac hypertrophy. <span><span class="ref-journal">Circulation research. </span>2011 Jan 21;<span class="ref-vol">108</span>(2):265–272.</span> [<a href="/pubmed/21252153" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Circulation+research&amp;title=TRPC+channels+as+effectors+of+cardiac+hypertrophy&amp;author=P+Eder&amp;author=JD+Molkentin&amp;volume=108&amp;issue=2&amp;publication_year=2011&amp;pages=265-272&amp;pmid=21252153&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">34. <span class="element-citation">Koitabashi N, Aiba T, Hesketh GG, Rowell J, Zhang M, Takimoto E, Tomaselli GF, Kass DA. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. <span><span class="ref-journal">Journal of molecular and cellular cardiology. </span>2010 Apr;<span class="ref-vol">48</span>(4):713–724.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2837762/">PMC free article</a>]</span> [<a href="/pubmed/19961855" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+molecular+and+cellular+cardiology&amp;title=Cyclic+GMP/PKG-dependent+inhibition+of+TRPC6+channel+activity+and+expression+negatively+regulates+cardiomyocyte+NFAT+activation+Novel+mechanism+of+cardiac+stress+modulation+by+PDE5+inhibition&amp;author=N+Koitabashi&amp;author=T+Aiba&amp;author=GG+Hesketh&amp;author=J+Rowell&amp;author=M+Zhang&amp;volume=48&amp;issue=4&amp;publication_year=2010&amp;pages=713-724&amp;pmid=19961855&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">35. <span class="element-citation">Kuwahara K, Wang Y, McAnally J, Richardson JA, Bassel-Duby R, Hill JA, Olson EN. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. <span><span class="ref-journal">The Journal of clinical investigation. </span>2006 Dec;<span class="ref-vol">116</span>(12):3114–3126.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1635163/">PMC free article</a>]</span> [<a href="/pubmed/17099778" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+Journal+of+clinical+investigation&amp;title=TRPC6+fulfills+a+calcineurin+signaling+circuit+during+pathologic+cardiac+remodeling&amp;author=K+Kuwahara&amp;author=Y+Wang&amp;author=J+McAnally&amp;author=JA+Richardson&amp;author=R+Bassel-Duby&amp;volume=116&amp;issue=12&amp;publication_year=2006&amp;pages=3114-3126&amp;pmid=17099778&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">36. <span class="element-citation">Patel A, Sharif-Naeini R, Folgering JR, Bichet D, Duprat F, Honore E. Canonical TRP channels and mechanotransduction: from physiology to disease states. <span><span class="ref-journal">Pflugers Arch. </span>2010 Aug;<span class="ref-vol">460</span>(3):571–581.</span> [<a href="/pubmed/20490539" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pflugers+Arch&amp;title=Canonical+TRP+channels+and+mechanotransduction:+from+physiology+to+disease+states&amp;author=A+Patel&amp;author=R+Sharif-Naeini&amp;author=JR+Folgering&amp;author=D+Bichet&amp;author=F+Duprat&amp;volume=460&amp;issue=3&amp;publication_year=2010&amp;pages=571-581&amp;pmid=20490539&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R37">37. <span class="element-citation">Kauppi M, Simonsen A, Bremnes B, Vieira A, Callaghan J, Stenmark H, Olkkonen VM. The small GTPase Rab22 interacts with EEA1 and controls endosomal membrane trafficking. <span><span class="ref-journal">Journal of cell science. </span>2002 Mar 1;<span class="ref-vol">115</span>(Pt 5):899–911.</span> [<a href="/pubmed/11870209" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+cell+science&amp;title=The+small+GTPase+Rab22+interacts+with+EEA1+and+controls+endosomal+membrane+trafficking&amp;author=M+Kauppi&amp;author=A+Simonsen&amp;author=B+Bremnes&amp;author=A+Vieira&amp;author=J+Callaghan&amp;volume=115&amp;issue=Pt+5&amp;publication_year=2002&amp;pages=899-911&amp;pmid=11870209&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R38">38. <span class="element-citation">Mesa R, Magadan J, Barbieri A, Lopez C, Stahl PD, Mayorga LS. Overexpression of Rab22a hampers the transport between endosomes and the Golgi apparatus. <span><span class="ref-journal">Exp Cell Res. </span>2005 Apr 1;<span class="ref-vol">304</span>(2):339–353.</span> [<a href="/pubmed/15748882" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Exp+Cell+Res&amp;title=Overexpression+of+Rab22a+hampers+the+transport+between+endosomes+and+the+Golgi+apparatus&amp;author=R+Mesa&amp;author=J+Magadan&amp;author=A+Barbieri&amp;author=C+Lopez&amp;author=PD+Stahl&amp;volume=304&amp;issue=2&amp;publication_year=2005&amp;pages=339-353&amp;pmid=15748882&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R39">39. <span class="element-citation">Mesa R, Salomon C, Roggero M, Stahl PD, Mayorga LS. Rab22a affects the morphology and function of the endocytic pathway. <span><span class="ref-journal">Journal of cell science. </span>2001 Nov;<span class="ref-vol">114</span>(Pt 22):4041–4049.</span> [<a href="/pubmed/11739636" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+cell+science&amp;title=Rab22a+affects+the+morphology+and+function+of+the+endocytic+pathway&amp;author=R+Mesa&amp;author=C+Salomon&amp;author=M+Roggero&amp;author=PD+Stahl&amp;author=LS+Mayorga&amp;volume=114&amp;issue=Pt+22&amp;publication_year=2001&amp;pages=4041-4049&amp;pmid=11739636&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R40">40. <span class="element-citation">Zhang HT, Wang WW, Ren LH, Zhao XX, Wang ZH, Zhuang DL, Bai YN. The mTORC2/Akt/NFkappaB Pathway-Mediated Activation of TRPC6 Participates in Adriamycin-Induced Podocyte Apoptosis. <span><span class="ref-journal">Cell Physiol Biochem. </span>2016;<span class="ref-vol">40</span>(5):1079–1093.</span> [<a href="/pubmed/27960162" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Physiol+Biochem&amp;title=The+mTORC2/Akt/NFkappaB+Pathway-Mediated+Activation+of+TRPC6+Participates+in+Adriamycin-Induced+Podocyte+Apoptosis&amp;author=HT+Zhang&amp;author=WW+Wang&amp;author=LH+Ren&amp;author=XX+Zhao&amp;author=ZH+Wang&amp;volume=40&amp;issue=5&amp;publication_year=2016&amp;pages=1079-1093&amp;pmid=27960162&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R41">41. <span class="element-citation">Huls M, Russel FG, Masereeuw R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. <span><span class="ref-journal">J Pharmacol Exp Ther. </span>2009 Jan;<span class="ref-vol">328</span>(1):3–9.</span> [<a href="/pubmed/18791064" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Pharmacol+Exp+Ther&amp;title=The+role+of+ATP+binding+cassette+transporters+in+tissue+defense+and+organ+regeneration&amp;author=M+Huls&amp;author=FG+Russel&amp;author=R+Masereeuw&amp;volume=328&amp;issue=1&amp;publication_year=2009&amp;pages=3-9&amp;pmid=18791064&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R42">42. <span class="element-citation">Solbach TF, Paulus B, Weyand M, Eschenhagen T, Zolk O, Fromm MF. ATP-binding cassette transporters in human heart failure. <span><span class="ref-journal">Naunyn Schmiedebergs Arch Pharmacol. </span>2008 May;<span class="ref-vol">377</span>(3):231–243.</span> [<a href="/pubmed/18392808" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Naunyn+Schmiedebergs+Arch+Pharmacol&amp;title=ATP-binding+cassette+transporters+in+human+heart+failure&amp;author=TF+Solbach&amp;author=B+Paulus&amp;author=M+Weyand&amp;author=T+Eschenhagen&amp;author=O+Zolk&amp;volume=377&amp;issue=3&amp;publication_year=2008&amp;pages=231-243&amp;pmid=18392808&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R43">43. <span class="element-citation">Zhou ZY, Wan LL, Yang QJ, Han YL, Li D, Lu J, Guo C. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model. <span><span class="ref-journal">Toxicol Lett. </span>2016 Sep 30;<span class="ref-vol">259</span>:124–132.</span> [<a href="/pubmed/27491883" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Toxicol+Lett&amp;title=Nilotinib+reverses+ABCB1/P-glycoprotein-mediated+multidrug+resistance+but+increases+cardiotoxicity+of+doxorubicin+in+a+MDR+xenograft+model&amp;author=ZY+Zhou&amp;author=LL+Wan&amp;author=QJ+Yang&amp;author=YL+Han&amp;author=D+Li&amp;volume=259&amp;publication_year=2016&amp;pages=124-132&amp;pmid=27491883&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R44">44. <span class="element-citation">Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR, Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. <span><span class="ref-journal">Cancer Research. </span>2008 Oct 1;<span class="ref-vol">68</span>(19):7905–7914.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2652245/">PMC free article</a>]</span> [<a href="/pubmed/18829547" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Lapatinib+(Tykerb,+GW572016)+reverses+multidrug+resistance+in+cancer+cells+by+inhibiting+the+activity+of+ATP-binding+cassette+subfamily+B+member+1+and+G+member+2&amp;author=CL+Dai&amp;author=AK+Tiwari&amp;author=CP+Wu&amp;author=XD+Su&amp;author=SR+Wang&amp;volume=68&amp;issue=19&amp;publication_year=2008&amp;pages=7905-7914&amp;pmid=18829547&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R45">45. <span class="element-citation">Cascales A, Pastor-Quirante F, Sanchez-Vega B, Luengo-Gil G, Corral J, Ortuno-Pacheco G, Vicente V, de la Pena FA. Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. <span><span class="ref-journal">The oncologist. </span>2013;<span class="ref-vol">18</span>(4):446–453.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3639532/">PMC free article</a>]</span> [<a href="/pubmed/23576480" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+oncologist&amp;title=Association+of+anthracycline-related+cardiac+histological+lesions+with+NADPH+oxidase+functional+polymorphisms&amp;author=A+Cascales&amp;author=F+Pastor-Quirante&amp;author=B+Sanchez-Vega&amp;author=G+Luengo-Gil&amp;author=J+Corral&amp;volume=18&amp;issue=4&amp;publication_year=2013&amp;pages=446-453&amp;pmid=23576480&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R46">46. <span class="element-citation">Ding Y, Liu W, Deng Y, Jomok B, Yang J, Huang W, Clark KJ, Zhong TP, Lin X, Ekker SC, Xu X. Trapping cardiac recessive mutants via expression-based insertional mutagenesis screening. <span><span class="ref-journal">Circ Res. </span>2013 Feb 15;<span class="ref-vol">112</span>(4):606–617.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3603352/">PMC free article</a>]</span> [<a href="/pubmed/23283723" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Circ+Res&amp;title=Trapping+cardiac+recessive+mutants+via+expression-based+insertional+mutagenesis+screening&amp;author=Y+Ding&amp;author=W+Liu&amp;author=Y+Deng&amp;author=B+Jomok&amp;author=J+Yang&amp;volume=112&amp;issue=4&amp;publication_year=2013&amp;pages=606-617&amp;pmid=23283723&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R47">47. <span class="element-citation">Ding Y, Long PA, Bos JM, Shih YH, Ma X, Sundsbak RS, Chen J, Jiang Y, Zhao L, Hu X, Wang J, Shi Y, Ackerman MJ, Lin X, Ekker SC, Redfield MM, Olson TM, Xu X. A modifier screen identifies DNAJB6 as a cardiomyopathy susceptibility gene. <span><span class="ref-journal">JCI Insight. </span>2016 Sep 8;<span class="ref-vol">1</span>(14)</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5023154/">PMC free article</a>]</span> [<a href="/pubmed/27642634" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JCI+Insight&amp;title=A+modifier+screen+identifies+DNAJB6+as+a+cardiomyopathy+susceptibility+gene&amp;author=Y+Ding&amp;author=PA+Long&amp;author=JM+Bos&amp;author=YH+Shih&amp;author=X+Ma&amp;volume=1&amp;issue=14&amp;publication_year=2016&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5581215&amp;issue-id=297737&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="#ui-ncbiinpagenav-heading-3">Associated Data</a></li><li><a href="#idm140277541413312title">Abstract</a></li><li><a href="#S5title">Introduction</a></li><li><a href="#S6title">Methods</a></li><li><a href="#S7title">Results</a></li><li><a href="#S11title">Discussion</a></li><li><a href="#S12title">Supplementary Material</a></li><li><a href="#S13title">Acknowledgments</a></li><li><a href="#idm140277501071072title">Footnotes</a></li><li><a href="#idm140277499928736title">References</a></li></ul></div></div><!--post-content--></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC5581215/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC5581215/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC5581215/pdf/nihms892344.pdf">PDF (393K)</a></li> | <li><a href="#" data-citationid="PMC5581215" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5581215%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5581215%2F&amp;text=Genome-wide%20association%20study%20of%20cardiotoxicity%20in%20NCCTG%20N9831%20(Alliance)%20Adjuvant%20Trastuzumab%20Trial" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5581215%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="28763429" data-aiid="5581215" data-aid="5581215" data-iid="297737" data-domainid="319" data-domain="nihpa" data-accid="PMC5581215" data-md5="b52ed54264e03828f41475cb9a23a076"><img src="/portal/portal3rc.fcgi/4018218/img/3631476" alt="Loading..." align="absmiddle"> Loading portlets...</div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-11-20T16:29:40-05:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=portal105&amp;ncbi_phid=CE8C098BDD5A65C10000000005E90382&amp;ncbi_session=CE8C6010DD4F8B31_0740SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5581215%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 68.1px; left: 377.2px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC5581215/&amp;ncbi_app=pmc" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C6010DD4F8B31_0740SID /projects/PMC/PMCViewer@4.46 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></html>